Prucalopride for Gastroparesis: A Four-Week Trial

If prucalopride has come up after a gastroparesis diagnosis, bring your test report and a record of meals, symptoms and medicines to the appointment. Ask which symptom the proposed treatment is meant to change and when you will review whether it has helped.

What improved?

Carbone’s trial enrolled 34 adults, 28 with idiopathic gastroparesis. Each treatment period lasted four weeks, comparing prucalopride 2 mg daily with placebo, separated by a two-week washout.¹

The primary symptom score, the Gastroparesis Cardinal Symptom Index (GCSI; 0–5), averaged 1.65 with prucalopride versus 2.28 with placebo (P<.0001); lower scores indicated less severe symptoms. Gastric emptying also accelerated, but its change did not correlate significantly with symptom improvement. That analysis did not establish why symptoms improved.¹

ACG describes gastroparesis assessment as testing stomach emptying and checking for a physical obstruction. Fullness or nausea alone does not establish the diagnosis. Ask your clinician to explain which findings support yours before discussing another prescription.²

How certain is the result?

Only 31 started treatment; 27 completed. Missing symptom values were carried forward. The analysis method changed during the trial; final models adjusted for order and period effects. Shire supported the study. One intestinal volvulus occurred during prucalopride treatment. This short, predominantly idiopathic study cannot establish lasting benefit or broad safety.¹

The 2025 AGA guideline conditionally suggests against prucalopride as first-line gastroparesis treatment, rating the evidence very low certainty. Its implementation advice allows an individual choice after discussing potential benefits and harms, particularly with idiopathic gastroparesis or coexisting chronic idiopathic constipation. Ask why it is being considered at this point in your treatment.³

Where does that leave prescribing?

US Motegrity labeling covers adult chronic idiopathic constipation, not gastroparesis. Prescribing it for gastroparesis is off-label. The label contraindicates intestinal obstruction or perforation and certain severe inflammatory bowel conditions. A prescriber must review kidney function; severe impairment requires a lower dose, and dialysis-dependent end-stage disease is a reason to avoid it. Discuss pregnancy, breastfeeding and your medicine list too.⁴

New or worsening depression, unusual mood or behavior changes, or emerging suicidal thoughts or behavior require stopping Motegrity immediately and contacting your healthcare provider. The label requires monitoring even though a causal association has not been established. Agree on a contact route and review date before starting.⁴

Bloated by Dinner includes “The Visit Script”: bring your symptom record, summarize the pattern, list medicines and supplements, and ask what has been ruled out and what comes next. Keep your stomach-emptying report with that record so the discussion starts from the tests you have actually had.